Deposition of aerosols in infants and children.
There is still a lack of knowledge in the field of aerosol therapy in children, particularly in young children. The amount of drug delivered from a commercially available inhalation device that reaches the lungs of children is generally low. The choice of an optimal combination of delivery device and drug formulation based on individual patient related factors is crucial. Aerosols with a small MMAD and a narrow GSD are required for a sufficient inhalation therapy in early childhood. The development of combinations of delivery devices and drug formulations fulfilling the requirements for an efficient inhalation therapy in young children is likely to increase the therapeutical options in this age group.
Swiss Paediatric Respiratory Research Group, Department of Respiratory Medicine, University Children's Hospital, Zurich, Switzerland.
Karen G
KG
Schüepp
Daniel
D
Straub
Alexander
A
Möller
Johannes H
JH
Wildhaber
D000280:Administration, Inhalation; D000336:Aerosols; D000367:Age Factors; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy; D001682:Biological Availability; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004867:Equipment Design; D004869:Equipment Safety; D005260:Female; D006801:Humans; D007223:Infant; D008168:Lung / Q000187:drug effects*; D008297:Male; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D012138:Respiratory Therapy / Q000295:instrumentation*; D012307:Risk Factors
D000336:Aerosols; D018927:Anti-Asthmatic Agents